https://www.selleckchem.com/products/tl13-112.html
73 m ). The trial will continue until ≥330 participants have had a major adverse CV event outcome and the sample size was based on accruing enough outcomes to detect non-inferiority of efpeglenatide versus placebo. Recruitment of 4076 participants (33% women, mean age 64.5 years) occurred between 11 May 2018 and 25 April 2019 at 344 sites in 28 countries. Mean baseline glycated haemoglobin was 8.9% (1.5), 31.6% had an eGFR 60 mL/min/1.73 m , 89.5% had previous CV disease and 15.0% were on an SGLT2 inhibitor. The results of the AMPL